{"id":"intensified-thiazide-treatment-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Ototoxicity (at high doses)"},{"rate":null,"effect":"Metabolic alkalosis"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thiazide diuretics block the sodium-chloride symporter (NCC) in the kidney's distal convoluted tubule, reducing intravascular volume and peripheral vascular resistance. This intensified treatment regimen uses higher doses or more frequent dosing of thiazide agents to achieve greater antihypertensive efficacy in resistant or difficult-to-control hypertension.","oneSentence":"Intensified thiazide treatment lowers blood pressure by increasing urinary sodium and water excretion through inhibition of sodium-chloride cotransport in the distal convoluted tubule.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:51.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (resistant or difficult-to-control)"}]},"trialDetails":[{"nctId":"NCT03319823","phase":"PHASE4","title":"Treating Nocturnal Hypertension and Nocturia in African American Men","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-25","conditions":"High Blood Pressure","enrollment":""},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT01921829","phase":"PHASE4","title":"Protocolized Diuretic Strategy in Cardiorenal Failure","status":"TERMINATED","sponsor":"Kelly V. Liang, MD","startDate":"2013-11","conditions":"Cardiac Failure, Renal Failure, Kidney Failure","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intensified Thiazide Treatment Group","genericName":"Intensified Thiazide Treatment Group","companyName":"Cedars-Sinai Medical Center","companyId":"cedars-sinai-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intensified thiazide treatment lowers blood pressure by increasing urinary sodium and water excretion through inhibition of sodium-chloride cotransport in the distal convoluted tubule. Used for Hypertension (resistant or difficult-to-control).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}